• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by INVO BioScience Inc.

    10/22/24 12:05:35 PM ET
    $INVO
    Medical/Dental Instruments
    Health Care
    Get the next $INVO alert in real time by email
    RW 1 formrw.htm

     

    NAYA BIOSCIENCES, INC.

    5582 Broadcast Court

    Sarasota, FL 34240

     

    October 21, 2024

     

    VIA EDGAR

    Securities and Exchange Commission

    Division of Corporate Finance

    100 F Street N.E.

    Washington, DC 20549

     

    Re: NAYA Biosciences, Inc. (File No. 333-276529)
       
      Request to Withdraw Registration Statement on Form S-4

     

    Ladies and Gentlemen:

     

    In accordance with Rule 477 under the Securities Act of 1933 (the “Securities Act”), NAYA Biosciences, Inc. (formerly known as INVO Bioscience, Inc.) (the “Registrant”) hereby respectfully requests withdrawal of its registration statement on Form S-4 (File No. 333-276529), filed with the Securities and Exchange Commission (the “Commission”) on January 16, 2024, together with all exhibits and amendments thereto collectively, (the “Registration Statement”), with such withdrawal to be effective as of the date hereof or as soon as practicable hereafter, on the grounds that such withdrawal is consistent with the public interest and the protection of investors as contemplated by paragraph (a) of Rule 477.

     

    The Registrant has concluded it is no longer necessary to register the securities subject to the Registration Statement. The Commission has not declared the Registration Statement effective under the Securities Act and no securities were sold thereunder.

     

    The Registrant respectfully requests that the Commission grant this request to withdraw the Registration Statement and issue an order granting the withdrawal of the Registration Statement (the “Order”) effective as of the date hereof or at the earliest practicable date hereafter. Please provide a copy of the Order to the Registrant’s counsel, Marc Indeglia of Glaser Weil Fink Howard Jordan & Shapiro LLP, via email at [email protected].

     

    The Registrant further requests that, in accordance with Rule 457(p) under the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.

     

    Please contact Marc Indeglia at (310) 282-6245 if you have any questions with respect to this request. Thank you in advance for your consideration.

     

      Very truly yours,
         
      NAYA Biosciences, Inc.
         
      By:  /s/ Steven Shum
        Steven Shum
        Chief Executive Officer

     

    cc: Marc A. Indeglia
      Glaser Weil Fink Howard Jordan & Shapiro LLP

     

     

    Get the next $INVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INVO

    DatePrice TargetRatingAnalyst
    1/19/2022$7.00Buy
    Maxim Group
    8/18/2021$5.75 → $5.25Buy
    Roth Capital
    More analyst ratings

    $INVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Szot Matthew K

      4 - INVO Bioscience, Inc. (0001417926) (Issuer)

      5/22/23 8:13:16 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Shum Steve

      4 - INVO Bioscience, Inc. (0001417926) (Issuer)

      5/22/23 8:09:50 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Ryan Barbara

      4 - INVO Bioscience, Inc. (0001417926) (Issuer)

      5/22/23 8:07:09 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care

    $INVO
    SEC Filings

    See more
    • SEC Form RW filed by INVO BioScience Inc.

      RW - NAYA Biosciences, Inc. (0001417926) (Filer)

      10/22/24 12:05:35 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - INVO Bioscience, Inc. (0001417926) (Filer)

      10/15/24 9:17:59 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - INVO Bioscience, Inc. (0001417926) (Filer)

      10/1/24 5:26:10 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care

    $INVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

      SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review board clearance to initiate patient enrollment in up to 7 academic centers for its clinical trial evaluating the safety and efficacy of NY-303, its GPC3-targeting NK Engager bispecific antibody, as a monotherapy for the treatment of hepatocellular carcinoma in patients n

      10/24/24 9:00:00 AM ET
      $INVO
      $NAYA
      Medical/Dental Instruments
      Health Care
    • INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

      SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (NASDAQ:INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune diseases through the merger of INVO Biosciences and NAYA Biosciences, today confirmed it has changed its corporate name to NAYA Biosciences Inc. and will begin trading under the new symbol "NAYA" at the market open on Tuesday, October 22, 2024. The CUSIP number for the Company's common stock will remain unchanged. The name and symbol change follows the Company's recent announcement on October 14th regarding the completion of its merger with NAYA Biosciences. The newly combine

      10/21/24 9:00:00 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

      SARASOTA, Fla. and MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience ("INVO") (NASDAQ:INVO) today announced it has closed its merger with NAYA Biosciences, a company dedicated to increasing patient access to breakthrough treatments in oncology and autoimmune diseases. The combined company expects to change its name to NAYA Biosciences and trade on the NASDAQ under the "NAYA" ticker. The combined company will continue to operate the revenue-generating fertility business as well as expand its focus to the development of first-in-class clinical-stage assets in oncology and autoimmune diseases. The combined company will be led by INVO Chief Executive Officer Steve Shum, INVO Chief Fina

      10/14/24 9:18:20 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care

    $INVO
    Leadership Updates

    Live Leadership Updates

    See more

    $INVO
    Financials

    Live finance-specific insights

    See more

    $INVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • INVO Bioscience Appoints Barbara Levy as Senior VP, Global Clinical Integration

      SARASOTA, Fla., July 14, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the appointment of Barbara Levy, M.D., FACOG, FACS as the Company's Senior VP, Global Clinical Integration. Dr. Levy is considered one of the most influential clinical executives in the world, recently serving as Vice President, Health Policy at the American College of Obstetricians and Gynecologists (ACOG) and chair of the American Medical Association/Specialty Society Relative Value Scale Update Committee.

      7/14/21 8:30:00 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO Bioscience Appoints Andrea Goren as Chief Financial Officer

      SARASOTA, Fla., June 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the appointment of Andrea Goren as the Company's chief financial officer. In a career approaching 27 years, Mr. Goren has extensive experience in numerous financial functions, including service as a public company CFO, company director, capital raising activities as well as mergers

      6/15/21 9:00:00 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO Bioscience Appoints Meryle Lynn Chamberlain to Lead Marketing for Global Brand Expansion

      SARASOTA, Fla., May 10, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, is pleased to announce the appointment of tenured women's health & fertility solution marketing professional, Meryle Lynn Chamberlain, as Director of Marketing, a newly created position within the company. Chamberlain brings over 15 years of marketing experience in the women's health field includi

      5/10/21 8:30:00 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO Reports Record Third Quarter 2023 Financial Results

      Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences SARASOTA, Fla., Nov. 13, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.

      11/13/23 4:01:00 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

      Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Aug. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its second quarter 2023, for the period ended June 30, 2023, after the market close on Monday, August 14, 2023. The Company has scheduled a conference call that same day, Monday, August 14, 2023, at 4:30 pm ET, to review the results.

      8/9/23 4:15:00 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • INVO Bioscience to Report First Quarter 2023 Financial Results on Monday, May 15, 2023

      Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., May 8, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced infertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its first quarter 2023, for the period ended March 31, 2023, after the market close on Monday, May 15, 2023. The Company has scheduled a conference call that same day, Monday, May 15, 2023, at 4:30 pm ET, to review the results.

      5/8/23 4:15:00 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by INVO BioScience Inc. (Amendment)

      SC 13G/A - INVO Bioscience, Inc. (0001417926) (Subject)

      2/6/24 10:24:52 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by INVO BioScience Inc. (Amendment)

      SC 13G/A - INVO Bioscience, Inc. (0001417926) (Subject)

      9/8/23 4:34:56 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by INVO BioScience Inc.

      SC 13G - INVO Bioscience, Inc. (0001417926) (Subject)

      8/11/23 4:18:49 PM ET
      $INVO
      Medical/Dental Instruments
      Health Care

    $INVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on INVO Bioscience with a new price target

      Maxim Group initiated coverage of INVO Bioscience with a rating of Buy and set a new price target of $7.00

      1/19/22 8:21:04 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care
    • Roth Capital reiterated coverage on INVO Bioscience with a new price target

      Roth Capital reiterated coverage of INVO Bioscience with a rating of Buy and set a new price target of $5.25 from $5.75 previously

      8/18/21 9:28:21 AM ET
      $INVO
      Medical/Dental Instruments
      Health Care